Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2003
10/16/2003US20030195233 Carbocyclic secondary amides such as 2-(4-fluoro-phenoxy) -N-(4-((2-hydroxy-3-methyl-benzoyl amino)-methyl)-benzyl)-nicotinamide, administered for prophylaxis of respiratory system disorders
10/16/2003US20030195229 Administering viricides such as N-nonenyl glucosamine, and optionally with mixtures of nucleosides, nucleotides, immunomodulators or immunostimulants for prophylaxis viral diseases
10/16/2003US20030195225 Acidification of drugs such as carbendazim, by mixing with buffers improving water solubility; anticarcinogenic agents
10/16/2003US20030195214 Cancer treatment
10/16/2003US20030195200 Compounds, their preparation and use
10/16/2003US20030195198 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
10/16/2003US20030195194 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis
10/16/2003US20030195189 For therapy of hyperproliferative diseases
10/16/2003US20030195186 Administration of a therapeutically effective amount of at least one acetylcholinesterase inhibitor
10/16/2003US20030195185 For therapy of cough, pain, anxiety, asthma, depression or alcohol abuse
10/16/2003US20030195184 Diagnosis and management of infection caused by chlamydia
10/16/2003US20030195171 Method for inhibiting bone resorption with an alendronate and vitamin D formulation
10/16/2003US20030195157 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
10/16/2003US20030195153 Comprises metalloproteinase (stromelysin) inhibitors
10/16/2003US20030195152 Polymeric conjugates of antitumor agents
10/16/2003US20030195144 Antimicrobial compounds and formulations
10/16/2003US20030195143 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteoanabolically active substance
10/16/2003US20030195140 Methods and compositions for improving sleep
10/16/2003US20030195139 For treating subject with abstinence syndrome due to nicotine, an opiate, cocaine, an amphetamine, a benzodiazipine and ethanol
10/16/2003US20030194803 Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
10/16/2003US20030194742 Diagnosis of tauopathies
10/16/2003US20030194732 For treating neoplastic diseases by testing responsiveness to interferons
10/16/2003US20030194453 Dietary supplement
10/16/2003US20030194439 Pharmaceutical dosage form for pulsatile delivery of methylphenidate
10/16/2003US20030194431 Delivering active ingredients or medicaments having diverse physical states (e.g., solid, liquid, gas or dispersion) into a single dosage, multi-compartment capsule.
10/16/2003US20030194430 Process for encapsulating multi-phase, multi-compartment capsules for therapeutic compositions
10/16/2003US20030194429 Primary and secondary capsules contain a nutraceutical, a vitamin, a dietary supplement and/or a mineral
10/16/2003US20030194428 Process for encapsulating multi-phase, multi-compartment capsules
10/16/2003US20030194406 P-cadherin as a target for anti-cancer therapy
10/16/2003US20030194395 Th1 cell adoptive immunotherapy
10/16/2003US20030194390 Alkyl cyanoacrylate and inhibitor and aggregate structure formed; alkyl fatty ester, opacifier; ablating tissue by blocking blood flow
10/16/2003US20030194375 Anti-epileptogenic agents
10/16/2003CA2513149A1 A human ribonucleotide reductase m2 subunit
10/16/2003CA2486480A1 Improved kavalactone profile
10/16/2003CA2481379A1 Medicinal composition comprising acat inhibitor and insuline resistance improving agent
10/16/2003CA2481377A1 Antihistamine-decongestant pharmaceutical compositions
10/16/2003CA2481090A1 Novel pancortin-pablo protein interactions and methods of use thereof
10/16/2003CA2480709A1 Method of improving absorption of vitamin e by a pet animal
10/16/2003CA2480505A1 Use of botulinum toxin for treating cardiovasular diseases
10/16/2003CA2480446A1 Method and dietary composition for improving lipid digestibility
10/16/2003CA2480311A1 Oligomeric compounds for the modulation of hif-1alpha expression
10/16/2003CA2480225A1 Methods for treating rosacea with pyridones
10/16/2003CA2480084A1 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
10/16/2003CA2480082A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003CA2479840A1 Redifferentiated cells for repairing cartilage defects
10/16/2003CA2479522A1 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
10/16/2003CA2479520A1 P38 kinase inhibitors for treating mucus hypersecretion_
10/16/2003CA2478227A1 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
10/16/2003CA2477298A1 Use of biomolecular targets in the treatment and visualization of brain tumors
10/15/2003EP1352972A2 Methods of identifying a pharmaceutically active compound for the treatment of a condition caused by altered expression of the insulin receptor
10/15/2003EP1352660A1 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
10/15/2003EP1352659A1 Combination drugs
10/15/2003EP1352658A1 Preventives or remedies for endometriosis
10/15/2003EP1352651A2 Novel use of orexin receptor antagonists
10/15/2003EP1352629A1 Use of a pyridine-dicarboxylic acid derivative or a salt thereof to stimulate or induce keratinic fiber growth and/or to prevent its loss
10/15/2003EP1352627A2 Reduction of hair growth
10/15/2003EP1352077A2 Materials and methods relating to protein aggregation in neurodegenerative disease
10/15/2003EP1352056A2 Polypeptides
10/15/2003EP1351985A2 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
10/15/2003EP1351980A2 Peptides for activation and inhibition of delta pkc
10/15/2003EP1351979A1 Regulated activation of cell-membrane receptors by metal-chelating agonists
10/15/2003EP1351969A1 Method for generating immortal dendritic cell lines
10/15/2003EP1351968A1 Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
10/15/2003EP1351967A2 Compositions and methods for the therapy and diagnosis of lung cancer
10/15/2003EP1351966A1 Improved specificity in treatment of diseases
10/15/2003EP1351957A1 Chemical derivatives and their use as anti-telomerase agent
10/15/2003EP1351956A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors
10/15/2003EP1351946A2 Materials and methods to potentiate cancer treatment
10/15/2003EP1351744A2 Erbb4 antagonists
10/15/2003EP1351742A2 Compositions for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
10/15/2003EP1351710A2 Compositions containing inclusion complexes
10/15/2003EP1351707A2 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/15/2003EP1351702A1 Trem-1 splice variant for use in modifying immune responses
10/15/2003EP1351701A2 Active metabolite of antifungal compound
10/15/2003EP1351694A1 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
10/15/2003EP1351693A1 Novel method and compositions for local treatment of meniere's disease, tinnitus and/or hearing loss
10/15/2003EP1351692A1 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
10/15/2003EP1351690A2 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance
10/15/2003EP1351686A2 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
10/15/2003EP1351683A2 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
10/15/2003EP1351682A1 Regulation of lipids and/or bone density and compositions therefor
10/15/2003EP1351681A2 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
10/15/2003EP1351679A2 Method and composition for the treatment of diabetic neuropathy
10/15/2003EP1351678A2 Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
10/15/2003EP1351675A2 Alpha-difluoromethylornithine (dfmo) use in the human prostate
10/15/2003EP1351670A1 Methods for treating neuropsychiatric disorders with nmda receptor antagonists
10/15/2003EP1351668A1 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
10/15/2003EP1351573A1 Methods for modulating tumor growth and metastasis
10/15/2003EP1173181B1 Composition comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction
10/15/2003EP0956019B1 Novel therapeutic application of a thienycyclohexylamine derivative
10/15/2003EP0876140B1 Improved kontrast agent solutions for intravenous administration
10/15/2003EP0831769B1 Novel uses for thyroid hormones or thyroid hormone-like compounds
10/15/2003CN1449493A Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
10/15/2003CN1449445A Ev-vegf nucleic acids and polypeptides and methods of use
10/15/2003CN1449440A Masp-2, a complement-fixing enzyme, and uses for it
10/15/2003CN1449410A Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
10/15/2003CN1449285A Use of il-8 receptor antagonists in the treatment of virus infections
10/15/2003CN1449280A Rapidly-decomposing administrable form for releasing active ingredients in the oral cavity or in bodily cavities
10/15/2003CN1449278A Lung surfactant compositions with dynamic swelling behaviour
10/15/2003CN1448184A Injectable pharmaceutical composition containing non-steroid antiphlogistic medicament and method for making same
1 ... 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 ... 1151